Novo Nordisk has made changes to its executive management team, shifting responsibilities and reducing the number of executives from seven to six. Executive vice president and chief of staffs, Lise Kingo has decided to leave the company. The remaining members of executive management team will take on her responsibilities.
 
Chief executive officer Lars Rebien Sorensen, said, “I would like to thank Lise for her many contributions to Novo Nordisk during her impressive career in the company. Of special note is her leadership in driving the company’s strategy within sustainable development, corporate branding and public affairs, which has earned Novo Nordisk recognition as a respected global business. I wish her the best of luck in the future.”
 
Kare Schultz, president and chief operating officer is responsible for sales and product supply. Jesper Brandgaard, executive vice president and chief financial officer is responsible for finance, legal, and investor relations. Lars Fruergaard Jorgensen, executive vice president is responsible for corporate IT, corporate quality, corporate development, corporate people & organization and business assurance. Jakob Riis, executive vice president is responsible for marketing, medical affairs and corporate stakeholder engagement, and Mads Krogsgaard Thomsen, executive vice president and chief science officer is responsible for R&D and regulatory affairs.